NLRP3 and colitis: Taken together, the present findings are in line with recent studies showing that treatment with MCC950, a potent and highly specific small molecule inhibitor of NLRP3 inflammasome counteracted bowel inflammation in a spontaneous colitis murine model (Winnie mice), and, that anakinra reduced post-operative inflammation and ameliorated post-operative ileus in mice (Stoffels et al., 2014; Perera et al., 2018).